With no Food and Drug Administration (FDA)-approved treatments available, patients confront a substantial unmet need.
TORONTO, Ontario, June 11, 2021 /PRNewswire-PRWeb/ -- Driven by rising rates of obesity and diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) have replaced hepatitis C virus infection as the most common cause of chronic liver disease worldwide. With no Food and Drug Administration (FDA)-approved treatments available, patients confront a substantial unmet need. However, the prospects for drug development have begun to brighten as understanding of liver disease pathophysiology, diagnosis, epidemiology and natural history evolve at a remarkable pace.
As this field of research continues to expand; however, high study competition and subject burden combined with limited availability of appropriately skilled hepatologists pose significant challenges for NASH clinical trials, particularly in patient enrollment and retention. Overcoming these challenges through a site-centric approach built on customized recruitment strategies, continuous site identification and site relationship management is key to accelerating the clinical development of NAFLD/NASH therapies.
This webinar will provide insights into this approach based on experience in more than 20 NAFLD/NASH clinical trials within the last five years across all study phases, with 3,000 patients enrolled across more than 1,000 clinical hepatologist sites across the world, with a focus on best practices for optimizing study operations, maximizing patient enrollment and ensuring study success.
Join experts from Syneos Health, Alastair D Smith, Executive Medical Director; Luiza Borowska, Executive Director, Clinical Development, Gastroenterology/Hepatology (Europe/Asia); and Hans-Juergen Gruss, Vice President, Clinical Development, Gastroenterology/Hepatology (Europe/Asia), for the live webinar on Monday, June 28, 2021 at 11am EDT (4pm BST/UK).
For more information, or to register for this event, visit Ensuring Success of NASH Trials: Best Practices for Optimizing Operations, Enrollment and Retention.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Ayesha Rashid, Xtalks, +1 (416) 977-6555 x 272, firstname.lastname@example.org